Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109,USA.
Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA.
Trends Pharmacol Sci. 2022 May;43(5):378-391. doi: 10.1016/j.tips.2022.02.005. Epub 2022 Mar 7.
The mutational and phenotypic landscape of tumors is dynamic, requiring constant monitoring of cancer patients to provide the most up-to-date and effective care. Circulating tumor cells (CTCs) obtained via liquid biopsy can provide tumor DNA, RNA, and protein information that can aid in the diagnosis, prognosis, and treatment of patients. There have been many recent studies and advances in using CTC enumeration, characterization, and expansion to provide personalized cancer treatment, validating the benefit of using CTCs as a biomarker in standard of care procedures. In this paper, we aim to summarize these advances, their limitations, and suggest future areas of study necessary to bring CTC analysis to clinics.
肿瘤的突变和表型景观是动态的，需要对癌症患者进行持续监测，以提供最新和最有效的治疗。通过液体活检获得的循环肿瘤细胞（CTC）可以提供肿瘤 DNA、RNA 和蛋白质信息，有助于患者的诊断、预后和治疗。最近有许多研究和进展，利用 CTC 的计数、特征和扩增来提供个性化的癌症治疗，验证了将 CTC 作为标准治疗程序中的生物标志物的益处。在本文中，我们旨在总结这些进展、它们的局限性，并提出将 CTC 分析引入临床所需的未来研究领域。
Zotero 插件